
|Articles|May 1, 2004
Medicare to cover PDT for select AMD patients
Washington, DC-The Centers for Medicare and Medicaid Services has begun to cover ocular photodynamic therapy (PDT) with verteporfin to treat select patients with subfoveal occult, but no classic choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) and subfoveal minimally classic CNV.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
Ocumetics reports first-in-human data investigational accommodating IOL in severe vision loss
3
EnVision Summit 2026: Ultimate gathering place for ophthalmic education
4
Sandoz Canada launches aflibercept biosimilar, Enzeevum
5




























